Metastatic melanoma to the brain: Surgery and radiation is still the standard of care

Current Treatment Options in Oncology

Volumn 14, Issue 2, 2013, Pages 264-279

  Nicholas, Sarah ^a,c   Mathios, Dimitrios ^b,c   Jackson, Christopher ^b,c   Lim, Michael ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c Bunting Blaustein Cancer Research Building ^*  (United States)

Author keywords

Ant PD1; Brain metastases; Craniotomy; Immunotherapy; Ipilimumab; Kinase inhibitors; Melanoma; Stereotactic radiosurgery; Vemurafenib; Whole brain radiation therapy

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CD137 ANTIBODY; DABRAFENIB; DACARBAZINE; DENDRITIC CELL VACCINE; FOTEMUSTINE; INTERLEUKIN 2; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE; OX44 ANTIBODY; PROGRAMMED DEATH 1 ANTIBODY; PROTEIN ANTIBODY; STEROID; SUNITINIB; TEMOZOLOMIDE; TRAMETINIB; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; VACCINE; VEMURAFENIB;

ADVANCED CANCER; ALOPECIA; ARTHRALGIA; ARTICLE; BRAIN METASTASIS; BRAIN SURGERY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; COLITIS; COMORBIDITY; CONSTIPATION; CRANIOTOMY; CYBERKNIFE; DIARRHEA; DROWSINESS; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG COST; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FUNCTIONAL STATUS; GAMMA KNIFE; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HEALTH CARE COST; HUMAN; HYPOPHYSITIS; KIDNEY CARCINOMA; LEUKOCYTE; LIVER TOXICITY; LUNG TOXICITY; MELANOMA; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PARESTHESIA; PHOTOSENSITIVITY; PRURITUS; RISK BENEFIT ANALYSIS; SEIZURE; SIDE EFFECT; SKIN CARCINOMA; SKIN PAPILLOMA; SKIN TINGLING; STEREOTACTIC RADIOSURGERY; SURVIVAL TIME; SYMPTOM; THROMBOCYTE; TOXIC HEPATITIS; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; INDOLES; MELANOMA; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES;

EID: 84877738475     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-013-0228-6     Document Type: Article

References (90)

1. de la Monte S, Moore G, Hutchins G. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res. 1983;43:3427-33.
2. Sampson J, Carter J, Friedman A, et al. Demographics, prognosis and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998;88:11-20.
3. Soffietti R, Ruda R, Mutani R. Management of brain metastases. J Neurol. 2002;249:1357-69.
4. Fife KM, Colman MH, Stevens GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004;22:1293-300.
5. Buchsbaum JC, Suh JH, Lee SY, et al. Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer. 2002;94:2265-72.
6. Essner R. Surgical treatment of malignant melanoma. Surg Clin North Am. 2003;83:109-56.
7. Weber JS, Amin A, Minor D, et al. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a Phase II trial. Melanoma Res. 2011;21:530-4. This paper is an important retrospective review of [42] focusing on the outcomes of 12 patients with prior, but not active, brain metastases. The data from this study showed efficacy in the patient population with brain metastases.
8. Liew DN, Kano H, Kondziolka D, et al. Outcome predictors of Gamma Knife surgery for melanoma brain metastases. J Neurosurg. 2011;114:769-79. This paper reviewed 333 patients with melanoma with brain lesions to determine prognostic factors for patients undergoing stereotactic radiosurgery. The large cohort with this specific diagnosis makes this a valuable publication.
9. Raizer JJ, Hwu WJ, Panageas KS, et al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol. 2008;10:199-207.
10. Deeken JF, Loscher W. The Blood-Brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res. 2007;13:1663-74.
11. Sloan AE, Nock CJ, Einstein DB. Diagnosis and treatment of melanoma brain metastasis: a literature review. Cancer Control. 2009;16:248-55.
12. Engelhardt B. The blood-central nervous system barriers actively control immune cell entry into the central nervous system. Curr Pharm Des. 2008;14:1555-65.
13. Pachter JS, de Vries HE, Fabry Z. The blood-brain barrier and its role in immune privilege in the central nervous system. J Neuropathol Exp Neurol. 2003;62:593-604.
14. Lampson LA, Hickey WF. Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from 'histologically normal' to that showing different levels of glial tumor involvement. J Immunol. 1986;136:4054-62.
15. Yang I, Han SJ, Kaur G, Crane C, Parsa AT. The role of microglia in central nervous system immunity and glioma immunology. J Clin Neurosci. 2010;17:6-10.
16. Steel CD, Hahto SM, Ciavarra RP. Peripheral dendritic cells are essential for both the innate and adaptive antiviral immune responses in the central nervous system. Virology. 2009;387:117-26.
17. Engelhardt B, Coisne C. Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. Fluids Barriers CNS. 2011;8:4.
18. Eichler AF, Chung E, Kodack DP, et al. The biology of brain metastases - translation to new therapies. Nat Rev Clin Oncol. 2011;8:344-56.
19. National Comprehensive Cancer Network Guidelines: Central Nervous System Cancers Version 2.2012. Available at http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp#cns. Accessed September 2012.
20. Bafaloukos D, Aravantinos G, Fountzilas G, et al. Docetaxel in combination with dacarbazine in patients with advanced melanoma. Oncology. 2002;63:333-7.
21. Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004;22:1118-25.
22. Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol. 2004;22:2101-7.
23. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158-66.
24. Patel PM, Suciu S, Mortier L, EORTC Melanoma Group, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer. 2011;47:1476-83.
25. Micromedex 2.0 Available at http://www.thomsonhc.com/micromedex2/ librarian Accessed on November 20, 2012.
26. Abrey LE, Christodoulou C. Temozolomide for treating brain metastases. Semin Oncol. 2001;28:34-42.
27. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96.
28. Paul MJ, Summers Y, Calvert AH, Rustin G, et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res. 2002;12:175-8.
29. Chiarion-Sileni V, Guida M, Ridolfi L, et al. Italian Melanoma Intergroup Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens. Br J Cancer. 2011;104:1816-21. This prospective trial looked out the outcome of CNS progression in patients with metastatic melanoma treated with standard systemic therapies temozolomide and dacarbazine and found no difference in progression to the brain.
30. Siena S, Crinò L, Danova M, et al. Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. Ann Oncol. 2010;21:655-61.
31. Devito N, Yu M, Chen R, Pan E. Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide. Anticancer Res. 2011;31:4537-43.
32. Margolin K, Atkins B, Thompson A, et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol. 2002;128:214-8.
33. Schild SE, Behl D, Markovic SN, et al. Brain metastases from melanoma: Is there a role for concurrent temozolomide in addition to whole-brain radiation therapy? Am J Clin Oncol. 2010;33:633-6.
34. Hardee ME, Formenti SC. Combining stereotactic radiosurgery and systemic therapy for brain metastases: a potential role for temozolomide. Front Oncol. 2012;2:99.
35. Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer. 1990;66:1873-8.
36. Quéreux G, Dréno B. Fotemustine for the treatment of melanoma. Expert Opin Pharmacother. 2011;12:2891-904.
37. Wilson D, Fast FDA. approval of melanoma drug. The New York Times. August 17, 2011. Available at http://prescriptions.blogs.nytimes.com/2011/08/17/fast- f-d-a-approval-of-melanoma-drug/. Accessed on November 20, 2012
38. Chikuma S, Bluestone JA. CTLA-4 and tolerance: the biochemical point of view. Immunol Res. 2003;28:241-53.
39. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155-64.
40. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23.
41. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-26.
42. Lebbe C, McDermott DF, Robert C, et al. Ipilimumab improves survival in previously treated, advanced melanoma patients with poor prognostic factors: subgroup analyses from a phase III trial. [Abstract 13240] Presented at 35th ESMO Congress Milan, Italy October 8-12 2010.
43. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15:5591-8.
44. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2011;13:459-65. First prospective trial using ipilimumab in patients specifically with brain metastases from melanoma.
45. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24:207-12.
46. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027-34.
47. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261-8.
48. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-54.
49. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-65.
50. Dillman RO, Cornforth AN, Depriest C, et al. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. J Immunother. 2012;35:641-9.
51. Simeone E, Ascierto PA. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. J Immunotoxicol. 2012;9:241-7.
52. Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol. 2010;37:508-16.
53. Davar D, Tarhini AA, Kirkwood JM. Adjuvant therapy for melanoma. Cancer J. 2012;18:192-202.
54. Eggermont AM, Suciu S, Testori A, et al. Long-Term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol. 2012;30:3810-8.
55. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135-47.
56. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-16.
57. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707-14.
58. Rochet NM, Kottschade LA, Markovic SN. Vemurafenib for melanoma metastases to the brain. N Engl J Med. 2011;365:2439-41. Initial case report showing potential efficacy of vemurafenib in a patient with melanoma brain metastases.
59. Dummer R, Rinderknecht J, Goldinger SM, et al. An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. [abstract 8548]. Presented at ASCO 2011 Chicago, Illinois; June 3-7 2011.
60. Basile KJ, Abel EV, Aplin AE. Adaptive upregulation of FOXD3 and resistance to PLX4032/ 4720-induced cell death in mutant B-RAF melanoma cells. Oncogene. 2012;31:2471-9.
61. Falchook GS, Long GV, Kurzrock R. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379:1893-901. Phase I prospective trial using dabrafenib in patients with brain metastases. It is important because it does not exclude patients with brain metastases, as traditionally is done in other Phase I trials of new drugs.
62. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 1470-2045. This paper is an important study of dabrafenib and provides information on efficacy in patients with metastatic melanoma to the brain with different BRAF mutations.
63. Falchook GS, Lewis KD, Infante JR, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012;8:782-9.
64. Sunitinib in treating patients with brain metastases caused by kidney cancer or melanoma. NCT00462982. Available at http://clinicaltrials.gov/ct2/ show/NCT00462982?term=nct00462982&rank=1. Accessed on October 20, 2012.
65. Fonkem E, Uhlmann EJ, Floyd SR, et al. Melanoma brain metastasis: overview of current management and emerging targeted therapies. Expert Rev Neurother. 2012;12:1207-15.
66. Wasif N, Bagaria SP, Ray P, Morton DL. Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol. 2011;104:111-5.
67. Wornom 3rd IL, Smith JW, Soong SJ, et al. Surgery as palliative treatment for distant metastases of melanoma. Ann Surg. 1986;204:181-5.
68. Sosman JA, Moon J, Tuthil R, et al.: A Phase 2 Trial of Complete Resection for Stage IV Melanoma Results of Southwest Oncology Group Clinical Trial S9430. Cancer 2011, 4740-6. This paper prospectively looked at 66 patients with Stage IV melanoma for outcomes after surgical resection. This paper found that surgical resection prolonged survival.
69. Ewend MG, Morris DE, Carey LA, et al. Guidelines for the initial management of metastatic brain tumors: role of surgery, radiosurgery, and radiation therapy. J Natl Compr Canc Netw. 2008;6:505-13.
70. Caudle AS, Ross MI. Metastasectomy for stage IV melanoma: for whom and how much? Surg Oncol Clin N Am. 2011;20:133-44.
71. Wu R, Forget MA, Chacon J, et al. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J. 2012;18:160-75.
72. Rades D, Bohlen G, Pluemer A, et al. Stereotactic radiosurgery alone versus resection plus whole-brain radiotherapy for 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients. Cancer. 2007;109:2515-21.
73. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10:1037-44. Patients with brain metastases were randomized to receive either radiosurgery alone or radiosurgery and WBRT. A greater cognitive decline was seen in patients receiving WBRT pointing to a serious risk of this treatment.
74. Selek U, Chang EL, Hassenbusch 3rd SJ, et al. Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys. 2004;59:1097-106.
75. Yu C, Chen JC, Apuzzo ML, et al. Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys. 2002;52:1277-87.
76. Doss LL, Memula N. The radioresponsiveness of melanoma. Int J Radiat Oncol Biol Phys. 1982;8:1131-4.
77. Hauswald H, Dittmar JO, Habermehl D, et al. Efficacy and toxicity of whole brain radiotherapy in patients with multiple cerebral metastases from malignant melanoma. Radiat Oncol. 2012;2:130.
78. Gondi V, Tome WA, Marsh J, et al. Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: safety profile for RTOG 0933. Radiother Oncol. 2010;95:327-31.
79. Samlowski WE, Watson GA, Wang M, Rao G, Klimo Jr P, Boucher K, et al. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS). Cancer. 2007;109:1855-62.
80. Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29:134-41. This paper published the results of a phase III trial looking at the effect of adding WBRT to treatment for patients with brain metastases. It found decreased local recurrence but no increase in survival.
81. Patil CG, Pricola K, Sarmiento JM, et al. Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases. Cochrane Database Syst Rev. 2012;12:9.
82. Hart MG, Grant R, Walker M, Dickinson HO. Surgical resection and whole brain radiation therapy versus whole-brain radiation therapy alone for single brain metastases. Cochrane Database Syst Rev. 2005;25(1):CD003292.
83. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295:2483-91.
84. Fogarty G, Morton RL, Vardy J, et al. Whole brain radiotherapy after local treatment of brain metastases in melanoma patients - a randomised phase III trial. BMC Cancer. 2011;11:142-50. This study is similar to Kocher et al. but will look specifically at the outcome in patients with melanoma, which is an understudied population of patients.
85. Di Giacomo AM, Ascierto PA, Pilla L, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 2012;13:879-86. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): An open-label, single-arm phase 2 trial.
86. Knisely JP, Yu JB, Flanigan J, et al. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg. 2012;117:227-33. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival.
87. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925-31.
88. Stamell EF, Wolchok JD, Gnjatic S, et al. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys 2012 (In press).
89. Ipilimumab and whole-brain radiation therapy or stereotactic radiosurgery in treating patients with melanoma with brain metastases. NCT01703507. Available at http://clinicaltrials.gov/ct2/show/NCT01703507. Accessed on October 20 Accessed on October 20, 2012.
90. Lal LS, Byfield SD, Chang EL, et al. Cost-effectiveness analysis of a randomized study comparing radiosurgery with radiosurgery and whole brain radiation therapy in patients with 1 to 3 brain metastases. Am J Clin Oncol. 2012;35:45-50.